As asthma often presents with obvious heterogeneous symptoms, Walsh believes that IL-4, IL-5, and IL-13 have considerable potential in the treatment of asthma, and anti-IL-5 monoclonal antibody prevents disease exacerbation in asthmatic patients [16]. Here, IL5 is linked to asthma.